Russia Says Its Enteromix Cancer Vaccine Has Achieved 100% Success Rate in Trials. Image: Times Now.
(The Post News)- Russia’s Federal Medical and Biological Agency (FMBA) said that its recently created cancer vaccine has successfully finished preclinical trials, marking a significant advancement in the field of cancer vaccine development.
According to Tass News, the announcement was made by FMBA head Veronika Skvortsova at the Eastern Economic Forum (EEF) in Vladivostok, during the 10th Eastern Economic Forum, held in Vladivostok from September 3 to 6 under the theme “The Far East: Cooperation for Peace and Prosperity.” The event gathered over 8,400 participants from more than 75 countries, featuring more than 100 thematic sessions across seven program tracks.
Skvortsova highlighted that the study lasted several years, with the final three years focused on necessary preclinical studies. She confirmed that the vaccine is now ready for use, and they are awaiting formal approval.
Skvortsova also pointed out that the preclinical trials confirmed the vaccine’s safety, even with repeated use, while demonstrating high efficacy. She explained that depending on the illness characteristics, they saw tumor size reductions and slower tumor progression of 60% to 80%, adding that the studies also demonstrated higher survival rates that were directly related to the vaccine.
Russia’s Cancer Vaccine to Start Colon Cancer
The first target for the vaccine will be colorectal cancer, but Skvortsova revealed that research is also advancing on vaccines for glioblastoma and certain types of melanoma, including ocular melanoma. These developments, she said, are at “advanced stages.”
Meanwhile, most people are familiar with vaccines that prevent infectious diseases such as measles or chickenpox; scientists are increasingly exploring vaccines as a tool to fight cancer. Unlike traditional vaccines, therapeutic cancer vaccines are designed to help the immune system recognize and attack cancer cells.
The American Cancer Society noted that vaccines are already available for some prostate and bladder cancers, while others are in development. Preventive vaccines, such as the human papillomavirus (HPV) vaccine, are also widely used to lower cancer risk.
Skvortsova stressed that the Russian breakthrough could mark a turning point in oncology. “This vaccine gives us hope that we can not only slow the progression of cancer but also significantly extend patients’ lives,” she said.
About the Author
